Detailed information for compound 183398

Basic information

Technical information
  • TDR Targets ID: 183398
  • Name: (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dib utylamino)-2-oxoethyl]-2-(2-pyridin-2-ylethyl )pyrrolidine-3-carboxylic acid
  • MW: 509.637 | Formula: C29H39N3O5
  • H donors: 1 H acceptors: 4 LogP: 2.23 Rotable bonds: 14
    Rule of 5 violations (Lipinski): 2
  • SMILES: CCCCN(C(=O)CN1C[C@@H]([C@H]([C@@H]1CCc1ccccn1)C(=O)O)c1ccc2c(c1)OCO2)CCCC
  • InChi: 1S/C29H39N3O5/c1-3-5-15-31(16-6-4-2)27(33)19-32-18-23(21-10-13-25-26(17-21)37-20-36-25)28(29(34)35)24(32)12-11-22-9-7-8-14-30-22/h7-10,13-14,17,23-24,28H,3-6,11-12,15-16,18-20H2,1-2H3,(H,34,35)/t23-,24+,28-/m1/s1
  • InChiKey: FIVLYOIAUYHSKL-FMGHJNRGSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxo-ethyl]-2-[2-(2-pyridyl)ethyl]pyrrolidine-3-carboxylic acid
  • (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-[2-(2-pyridyl)ethyl]-3-pyrrolidinecarboxylic acid
  • (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxo-ethyl]-2-(2-pyridin-2-ylethyl)pyrrolidine-3-carboxylic acid
  • (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-keto-ethyl]-2-[2-(2-pyridyl)ethyl]pyrrolidine-3-carboxylic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Endothelin receptor ET-A Starlite/ChEMBL References
Homo sapiens endothelin receptor type B Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus multilocularis pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 21.1 %
Echinococcus granulosus pyroglutamylated rfamide peptide receptor Endothelin receptor ET-A   426 aa 412 aa 20.1 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni retinoblastoma binding protein 0.014 0.0958 0.0872
Echinococcus granulosus protein will die slowly 0.0759 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0081 0.0094 0.0094
Toxoplasma gondii SPRY domain-containing protein 0.0075 0 0.5
Loa Loa (eye worm) SPRY domain-containing protein 0.0081 0.0094 0.0094
Trichomonas vaginalis retinoblastoma binding protein, putative 0.014 0.0958 0.0958
Onchocerca volvulus 0.0759 1 0.5
Trichomonas vaginalis conserved hypothetical protein 0.014 0.0958 0.0958
Loa Loa (eye worm) WD40 repeat protein 0.0759 1 1
Schistosoma mansoni hypothetical protein 0.0759 1 1
Trichomonas vaginalis WD repeat domain, putative 0.0759 1 1
Echinococcus multilocularis protein will die slowly 0.0759 1 1
Echinococcus granulosus wd40 repeat 0.014 0.0958 0.0872
Trichomonas vaginalis conserved hypothetical protein 0.0081 0.0094 0.0094
Echinococcus multilocularis wd40 repeat 0.014 0.0958 0.0872
Brugia malayi Hypothetical WD-repeat protein F21H12.1 in chromosome II 0.014 0.0958 0.0872
Loa Loa (eye worm) hypothetical protein 0.014 0.0958 0.0958
Plasmodium vivax hypothetical protein, conserved 0.0081 0.0094 0.5
Plasmodium falciparum SPRY domain, putative 0.0081 0.0094 0.5

Activities

Activity type Activity value Assay description Source Reference
AUC (ADMET) = 0.78 ug hr ml-1 Pharmacokinetic profile AUC of the compound was evaluated in rats ChEMBL. 9703472
Cmax (ADMET) = 0.58 ug ml-1 Pharmacokinetic profile Cmax of the compound was evaluated in rats ChEMBL. 9703472
F (ADMET) = 21.1 % Bioavailability in rat ChEMBL. 9703472
IC50 (binding) = 0.29 nM Tested for binding affinity for human Endothelin A receptor by measuring its ability to displace [125I]-ET-1 from chinese hamster ovary cells(CHO) ChEMBL. 9703472
IC50 (binding) = 0.29 nM Tested for binding affinity for human Endothelin A receptor by measuring its ability to displace [125I]-ET-1 from chinese hamster ovary cells(CHO) ChEMBL. 9703472
IC50 (binding) = 0.38 nM Binding affinity for endothelin A receptor by measuring its ability to displace [125I]-ET-1 from prolactin secreting rat pituitary cells(MMQ) ChEMBL. 9703472
IC50 (binding) = 0.38 nM Binding affinity for endothelin A receptor by measuring its ability to displace [125I]-ET-1 from prolactin secreting rat pituitary cells(MMQ) ChEMBL. 9703472
IC50 (binding) = 0.72 nM Binding affinity for endothelin A receptor by measuring its ability to displace [125I]-ET-1 from prolactin secreting rat pituitary cells(MMQ) ChEMBL. 9703472
IC50 (binding) = 0.72 nM Binding affinity for endothelin A receptor by measuring its ability to displace [125I]-ET-1 from prolactin secreting rat pituitary cells(MMQ) ChEMBL. 9703472
IC50 (binding) = 14100 nM Binding affinity for endothelin B receptor by measuring its ability to displace [125I]-ET-3 from porcine cerebellar tissue ChEMBL. 9703472
IC50 (binding) = 14100 nM Binding affinity for endothelin B receptor by measuring its ability to displace [125I]-ET-3 from porcine cerebellar tissue ChEMBL. 9703472
IC50 (binding) = 26000 nM Binding affinity for endothelin B receptor by measuring its ability to displace [125I]-ET-3 from porcine cerebellar tissue ChEMBL. 9703472
IC50 (binding) = 26000 nM Binding affinity for endothelin B receptor by measuring its ability to displace [125I]-ET-3 from porcine cerebellar tissue ChEMBL. 9703472
IC50 (binding) = 32000 nM Tested for binding affinity for human Endothelin B receptor by measuring its ability to displace [125I]-ET-3 from chinese hamster ovary cells(CHO) ChEMBL. 9703472
IC50 (binding) = 32000 nM Tested for binding affinity for human Endothelin B receptor by measuring its ability to displace [125I]-ET-3 from chinese hamster ovary cells(CHO) ChEMBL. 9703472
Ratio (binding) = 37000 Inhibitory selectivity ratio for pETB / ETA ChEMBL. 9703472
T1/2 (ADMET) = 2.8 hr Pharmacokinetic profile-half life of the compound was evaluated in rats upon intravenous administration ChEMBL. 9703472
T1/2 (ADMET) = 8.8 hr Pharmacokinetic profile-half life of the compound was evaluated in rats upon oral administration ChEMBL. 9703472

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.